Myriad Genetics, Inc.
MYGN
$10.18
-$0.34-3.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 837.60M | 823.60M | 802.20M | 774.20M | 753.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 837.60M | 823.60M | 802.20M | 774.20M | 753.20M |
| Cost of Revenue | 252.20M | 254.10M | 248.20M | 241.60M | 236.20M |
| Gross Profit | 585.40M | 569.50M | 554.00M | 532.60M | 517.00M |
| SG&A Expenses | 560.60M | 569.00M | 566.00M | 561.80M | 567.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 925.50M | 924.60M | 911.20M | 894.50M | 892.10M |
| Operating Income | -87.90M | -101.00M | -109.00M | -120.30M | -138.90M |
| Income Before Tax | -123.40M | -116.60M | -156.60M | -235.50M | -262.20M |
| Income Tax Expenses | 3.90M | -600.00K | -1.40M | -900.00K | 1.10M |
| Earnings from Continuing Operations | -127.30 | -116.00 | -155.20 | -234.60 | -263.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -127.30M | -116.00M | -155.20M | -234.60M | -263.30M |
| EBIT | -87.90M | -101.00M | -109.00M | -120.30M | -138.90M |
| EBITDA | -26.70M | -39.50M | -54.70M | -67.80M | -82.70M |
| EPS Basic | -1.40 | -1.30 | -1.81 | -2.82 | -3.20 |
| Normalized Basic EPS | -0.61 | -0.71 | -0.79 | -0.91 | -1.09 |
| EPS Diluted | -1.41 | -1.31 | -1.82 | -2.83 | -3.21 |
| Normalized Diluted EPS | -0.61 | -0.71 | -0.79 | -0.91 | -1.09 |
| Average Basic Shares Outstanding | 362.50M | 357.50M | 348.50M | 339.60M | 331.00M |
| Average Diluted Shares Outstanding | 362.50M | 357.50M | 348.50M | 339.60M | 331.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
